Sign in
TerminatedNo phase

Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT) in Recurrent Rectal Cancer

Key facts

Who runs it
Washington University School of Medicine
Where
St Louis, United StatesSee the site
Trial code
Status
Terminated
People taking part
15 people enrolled
Started
4 May 2021
Ended
18 Nov 2024
Type of study
Interventional, 4 groups
Treatments tested
  • Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy
  • MEVION S250i Hyperscan and Adaptive Aperture Proton Therapy Machine
Record updated
29 September 2025
Why it stopped
Slow enrollment

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • History of biopsy-proven adenocarcinoma of the rectum, anus or rectosigmoid junction of any stage now with recurrent disease in the pelvis
  • One prior course of radiation therapy to the pelvis for rectal cancer
  • ECOG performance status 0-2
  • At least 18 years of age
  • Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately
  • Able to understand and willing to sign an IRB-approved written informed consent document

Who cannot take part

  • More than one prior course of radiation to the pelvis for rectal cancer
  • Prior radiation to the pelvis for disease other than rectal cancer
  • Tumor in the rectum/colon requiring radiation therapy to the full circumference of the rectum/colon
  • Current treatment with any investigational agents
  • Patients with pre-existing radiosensitizing conditions, such as connective tissue disorders (i.e. lupus, scleroderma) and genetic mutations (i.e. ataxia-telangiectasia)
  • A history of other malignancy with the exception of malignancies for which all treatment was completed at least 2 years before registration and the patient has no evidence of disease, basal cell or squamous cell carcinoma of the skin that were treated with local resection only, or carcinoma in situ of the cervix. Patients with history of prostate cancer treated without radiotherapy and no evidence of disease are eligible
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or unstable angina pectoris
  • Pregnant and/or breastfeeding. Women of childbearing potential must have a negative urine or serum pregnancy test within 14 days of study entry

Where in United States

  • Washington University School of MedicineSt Louis, United States

About the trial

What the trial wants to find out

The purpose of this trial is to determine the maximum tolerated dose (MTD) of hypofractionated IMPT for the reirradiation of locoregionally recurrent rectal cancer.

The 4 groups in the trial

  • Dose Level 1: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT)Treatment being tested

    * Radiotherapy will consist of five fractions, delivered once daily, with pencil beam scanning proton beam therapy using the defined dose in dose level 1 (30 Gy). * The use of Intensity Modulated Radiation Therapy (IMRT) with photon beam therapy is permitted at the discretion of the treating investigator in order to avoid extended treatment delays due to logistical reasons (e.g. machine downtime).

    Treatment: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy and MEVION S250i Hyperscan and Adaptive Aperture Proton Therapy Machine

  • Dose Level 2: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT)Treatment being tested

    * Radiotherapy will consist of five fractions, delivered once daily, with pencil beam scanning proton beam therapy using the defined dose in dose level 2 (35 Gy). * The use of Intensity Modulated Radiation Therapy (IMRT) with photon beam therapy is permitted at the discretion of the treating investigator in order to avoid extended treatment delays due to logistical reasons (e.g. machine downtime).

    Treatment: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy and MEVION S250i Hyperscan and Adaptive Aperture Proton Therapy Machine

  • Dose Level 3: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT)Treatment being tested

    * Radiotherapy will consist of five fractions, delivered once daily, with pencil beam scanning proton beam therapy using the defined dose in dose level 3 (40 Gy). * The use of Intensity Modulated Radiation Therapy (IMRT) with photon beam therapy is permitted at the discretion of the treating investigator in order to avoid extended treatment delays due to logistical reasons (e.g. machine downtime).

    Treatment: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy and MEVION S250i Hyperscan and Adaptive Aperture Proton Therapy Machine

  • Dose Level -1: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT)Treatment being tested

    * Radiotherapy will consist of five fractions, delivered once daily, with pencil beam scanning proton beam therapy using the defined dose in dose level -1 (25 Gy). * The use of Intensity Modulated Radiation Therapy (IMRT) with photon beam therapy is permitted at the discretion of the treating investigator in order to avoid extended treatment delays due to logistical reasons (e.g. machine downtime).

    Treatment: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy and MEVION S250i Hyperscan and Adaptive Aperture Proton Therapy Machine

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT) in the Reirradiation of Locoregionally Recurrent Rectal Cancer - IMPARC
Record updated
29 September 2025